The cardiovascular pharmaceuticals market into five regions: North America, Latin America, Europe, Asia Pacific, Africa, and the Middle East. The global cardiovascular pharmaceuticals market is oligopolistic, with a few companies controlling the majority of the market. Key market players use a variety of techniques to maintain their market position, including new product releases and alliances. For example, in December 2017, Medicure Inc., a Canadian pharmaceutical company, obtained a seven-year exclusive licence to market and sell a cardiovascular drug for the treatment of primary hyperlipidemia or mixed dyslipidemia in the United States and its territories through its subsidiary Medicure International Inc. The US Food and Drug Administration (FDA) approved Sun Pharmaceutical Industries' subsidiary in the United States to sell generic versions of its Coreg CR in October 2017. Coreg CR is a medication that is used to treat a variety of cardiac problems, including high blood pressure and heart failure. Takeda Pharmaceutical Company Limited and Cardurion Pharmaceuticals announced their collaboration in August 2017 to develop next-generation therapeutics for the treatment of cardiovascular disorders and heart failure.
Read More:
https://bloggerstrive.blogspot.com/2022/03/cardiovascular-drugs-market-overview.html
Click here for Cardiovascular Drugs Market Report:
https://www.coherentmarketinsights.com/market-insight/cardiovascular-drugs-market-1167
